




Case #2: Patient with RCC Stage IV, Age 66, Female, Prior TKI **Duration of Treatment Prior Therapies** Sunitinib ~8 mos (AE disc.) ~1.5 mos **NKTR-214** ~1.5 mos (SD) ~1 mo **Therapies Administered** Nivolumab >9 mos Ongoing Nivolumab plus investigational agent ~1mo Scan unavailable Confirmed due to enrollmen PR in another clinical trial Pre NKTR-214 EOT NKTR-214 Pre Nivolumab Post Nivolumab (RECIST 1.1: Maximum tumor response -20% on Pseudo progression (1st scan PR) NKTR-214) observed **NEKTAR** ASCO 2017 10

































f June 1, 2017)			
Patient Characteristics Safety Population: Dose Escalation	N=20		
Sex			
Male	15		
Female	5		
Age (years)			
Median		58	
Range		22-70	
Tumor Type			
Melanoma (0-1 prior therapies)	8		
Renal Cell Carcinoma (0-1 prior therapies)	9		
Non-Small Cell Lung Cancer (0-1 prior therapies)	3		
Stage			
Unresectable Stage III	1		
IV	19		
ECOG Performance Status (0-1)	20		
Prior Therapies			
Chemotherapy	2		
Cancer Vaccine	2		
Targeted Therapy (TKI or anti-VEGF)	3		


PIVOT Dose Escalation: Treatment-Related Adverse Events

- No DLTs or grade 3/4 treatment-related adverse events (TRAEs)
- No grade 3 or above immune-related AEs observed to date
- No patients discontinued treatment due to AE and no deaths


AE, N (%)	Total (N=20)	NKTR-214 0.006 mg/kg q3w + Nivo 240 mg q2w (N=4)	NKTR-214 0.006 mg/kg q3w + Nivo 360 mg q3w (N=10)	NKTR-214 0.006 mg/kg q2w + Nivo 240 mg q2w (N=3)	NKTR-214 0.003 mg/kg q2w + Nivo 240mg q2w (N=3)
≥ G3 AE Reported	0	0	0	0	0
Grade 1&2 (>25%)					
Fatigue	15 (75)	4 (100)	6 (60)	2 (67)	3 (100)
Flu-Like Symptoms*	15 (75)	3 (75)	7 (70)	3 (100)	2 (67)
Rash**	12 (60)	4 (100)	5 (50)	1 (33)	2 (67)
Pruritus	11 (55)	2 (50)	5 (50)	2 (67)	2 (67)
Headache	9 (45)	3 (75)	4 (40)	1 (33)	1 (33)
Flushing	8 (40)	3 (75)	2 (20)	2 (67)	1 (33)
Decreased Appetite	6 (30)	3 (75)	1 (10)	2 (67)	0
* Flu-like symptoms includes the foll **Rash includes the following MedD				ar.	
NEKTAR					ASCO 2017 20










































				_
	Patient	Prior Therapy	Dose	Ongoing Response
	#1	Pazopanib (PD)	NKTR-214 0.006 mg/kg Q3W + Nivolumab 240 mg Q2W	PR (-39%), Week 15
	#2	Bevacizumab (PD)	NKTR-214 0.006 mg/kg Q2W + Nivolumab 240 mg Q2W (first scan only)	SD (-9%), Week 8
ſ	#3	None	NKTR-214 0.006 mg/kg Q2W + Nivolumab 240 mg Q2W	SD (0%), Week 7
	#4	Sunitinib (PD)	NKTR-214 0.003 mg.kg Q2W + Nivolumab 240 mg Q2W	SD (-4%), Week 7
/ \	#5	Adjuvant oncophage vaccine (relapsed)	NKTR-214 0.003 mg.kg Q2W + Nivolumab 240 mg Q2W	SD (-9%), Week 7
	#6	None	NKTR-214 0.006 mg.kg Q3W + Nivolumab 360 mg Q3W	SD of target lesions, PD of non- target lesion, Week 7







NKTR-214 + Nivolumab Combination: Conclusions to Date


Enrolling patients to dose escalation of PIVOT 02 to identify the RP2D
 Last dosing cohort NKTR-214 0.009 mg/kg q3w + nivo 360 mg q3w


- Favorable safety profile and well tolerated combination
 - Low-grade AEs are predictable, manageable and of short duration
 - No DLTs and grade 3 or above TRAEs
 - No immune-related AEs were observed to date (e.g. colitis, dermatitis, hepatitis, pneumonitis, adrenal insufficiency)
- Clinical benefit observed early with NKTR-214 and Nivolumab
 - Responses in 3/5 patients with Stage IV Melanoma (1 CR, 2 PR)
 Time to responses: 6 weeks, 7 weeks, 20 weeks
 - PR in RCC patient who progressed on prior TKI (PD-L1 negative)
 - Responses in 3/4 RCC IO naïve patients with SD on NKTR-214 who received sequential therapy with Nivolumab
 - Total time on treatment to reach response is much shorter with concurrent dosing
- On treatment biopsies show robust elevation in immune cell frequency and activation
- Anticipate enrollment to expansion cohorts in 3Q 2017

NEKTAR


ASCO 2017 34


































































































NEKTAR

ASCO 2017 59

